Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar;60(2):187-196.
doi: 10.1016/j.resinv.2021.11.004. Epub 2021 Dec 16.

Bronchiectasis in severe asthma and asthmatic components in bronchiectasis

Affiliations
Review

Bronchiectasis in severe asthma and asthmatic components in bronchiectasis

Hisako Matsumoto. Respir Investig. 2022 Mar.

Abstract

Asthma and bronchiectasis are different diseases; however, differentiating them can be difficult because they share several symptomatic and physiological similarities. Approximately 20% of patients with bronchiectasis have eosinophilic inflammation, 34% show wheezing, and 7-46% have comorbid asthma, although comorbidity with severe asthma may be limited as shown in 3.3% of cases of bronchiectasis. Meanwhile, 25-68% of patients with severe asthma have comorbid bronchiectasis, and at least two phenotypes are present in the accompanying bronchiectasis: eosinophilic bronchiectasis and chronic infectious bronchiolitis/bronchiectasis. Recent studies show that type-2-targeted biologics are effective for eosinophilic bronchiectasis and theoretically effective for some of the remaining cases when used before oral corticosteroids. Further studies are needed to identify treatment strategies for severe asthma with comorbid bronchiectasis and vice versa.

Keywords: Bronchiectasis; Chronic infectious bronchiolitis; Exhaled nitric oxide; Severe asthma.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Dr. Matsumoto received lecturer fees from AstraZeneca K.K., Novartis Pharma K.K., GlaxoSmithKline K.K., Sanofi K.K., and KYORIN Pharmaceutical Co. Ltd. and research funding from Novartis Pharma K.K.